



# KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy

Chiara Ambrogio,<sup>1,2</sup> Ernest Nadal,<sup>3</sup> Alberto Villanueva,<sup>4,5</sup> Gonzalo Gómez-López,<sup>6</sup> Timothy P Cash,<sup>7</sup> Mariano Barbacid,<sup>1</sup> David Santamaría<sup>1</sup>

**To cite:** Ambrogio C, Nadal E, Villanueva A, *et al*. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. *ESMO Open* 2016;1:e000076. doi:10.1136/esmoopen-2016-000076

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/esmoopen-2016-000076>).

Received 16 May 2016  
Revised 25 July 2016  
Accepted 29 July 2016

## ABSTRACT

Understanding the early evolution of cancer heterogeneity during the initial steps of tumorigenesis can uncover vulnerabilities of cancer cells that may be masked at later stages. We describe a comprehensive approach employing gene expression analysis in early lesions to identify novel therapeutic targets and the use of mouse models to test synthetic lethal drug combinations to treat human Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven lung adenocarcinoma.

## INTRODUCTION

Understanding the early evolution of cancer heterogeneity during the initial steps of tumorigenesis can uncover vulnerabilities of cancer cells that may be masked at later stages. We describe a comprehensive approach employing gene expression analysis in early lesions to identify novel therapeutic targets and the use of mouse models to test synthetic lethal drug combinations to treat human Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven lung adenocarcinoma.

## Non-small cell lung cancer classification

Lung cancer is the leading cause of cancer-related mortality worldwide, with an average 5-year survival of 15%.<sup>1</sup> Non-small cell lung carcinoma (NSCLC), the most common type of lung cancer, encompasses three distinct histological subtypes: adenocarcinoma, squamous carcinoma and large cell carcinoma. During the previous decade, lung adenocarcinomas have been further subclassified based on the presence of driver mutations occurring in oncogenes such as *KRAS*, *BRAF* and *EGFR* or gene rearrangements in the *ALK* and *ROS1* loci.<sup>2</sup> Though *KRAS* mutations were the first genetic lesions identified in lung adenocarcinoma, having been discovered over 30 years ago,<sup>3</sup> the clinical value of determining the mutational status of *KRAS* in tumours is still controversial. Several

studies have shown that lung adenocarcinomas harbouring *KRAS* mutations have worse overall survival.<sup>4–6</sup> However, in a large study based on 1500 resected NSCLC, *KRAS* mutations were neither prognostic nor predictive for outcome after adjuvant chemotherapy.<sup>7</sup> More recent studies indicate that *KRAS* mutations are not predictive for therapeutic benefit for either docetaxel or erlotinib.<sup>8</sup> Given the lack of consistent prognostic value associated with *KRAS* mutational status alone, there is an urgent need to identify additional genetic alterations and therapeutic targets in patients with *KRAS*-mutant lung adenocarcinoma.

## KRAS-mutant lung adenocarcinoma

*KRAS* is the most commonly mutated oncogene in lung adenocarcinoma, with mutations detected in about 30% of patients. Though the recent development of *KRAS*<sup>G12C</sup> allosteric inhibitors offers promise, significant previous efforts to fully develop drugs that directly target mutant *KRAS* have largely failed, highlighting the need for alternative therapeutic approaches.<sup>9–10</sup> Studies employing genetically engineered mouse (GEM) tumour models<sup>11</sup> have recently identified novel targets in *Kras*-mutated adenocarcinomas and inhibitors for some of these targets have already entered clinical trials, though their clinical efficacy remains to be established.<sup>12</sup> One such study using GEMs demonstrated that lung adenocarcinomas with activated *Kras* were very sensitive to the MEK inhibitor selumetinib in combination with docetaxel treatment. However, tumours with mutated *Kras* and *Lkb1* loss did not benefit from the addition of selumetinib to docetaxel.<sup>13</sup> In a phase II clinical trial on patients with lung cancer, selumetinib plus docetaxel significantly improved progression-free survival in patients with *KRAS*-mutant lung adenocarcinoma resulting in a trend

For numbered affiliations see end of article.

**Correspondence to**  
Dr Chiara Ambrogio;  
[chiara\\_ambrogio@dfci.harvard.edu](mailto:chiara_ambrogio@dfci.harvard.edu)

towards increased overall survival.<sup>14</sup> However, there was greater toxicity, as indicated by febrile neutropenia, diarrhoea, nausea, vomiting and rash in patients treated with combination therapy compared to those treated with single agents. Another ongoing randomised phase III clinical trial is currently being carried out in patients with NSCLC with KRAS mutations to compare the efficacy of abemaciclib (a potent CDK4/6 inhibitor) with the best supportive care (BSC) versus erlotinib with BSC.<sup>15</sup> This study is based on the synthetic lethality observed between oncogenic KRAS and CDK4 inhibition in murine preclinical models.<sup>16</sup>

### Lung tumour heterogeneity

The results summarised above collectively suggest that human KRAS mutant tumours have diverse treatment responses, which depend on their genetic background. Indeed, advanced lung adenocarcinomas carry a substantial degree of genetic heterogeneity, which represents a major obstacle to therapeutic success, and a potential source of relapse.<sup>17</sup> During the past few years, next-generation sequencing has uncovered a large number of previously unknown alterations in lung adenocarcinoma, and this number will undoubtedly grow as more tumours are analysed.<sup>12</sup> A fundamental challenge that remains is how to differentiate aberrations that are functionally relevant for lung carcinogenesis and/or treatment response from non-relevant passenger mutations. Although genetic heterogeneity exists in the majority of solid tumours, it presents even greater difficulties in lung adenocarcinoma, which has the highest burden of somatic mutations following malignant melanoma.<sup>18</sup> This genetic heterogeneity in tumours is likely to impact gene transcription and may well have hindered previous attempts to clearly identify oncogene-specific gene expression signatures in human lung cancers carrying *KRAS* mutations, which only became apparent when compared to signatures present in *Kras*-driven mouse tumours.<sup>19</sup> Additionally, the fact that gene expression signatures from *KRAS* wild-type tumours have more prognostic power than those from *KRAS* mutant tumours most likely reflects increased genetic heterogeneity in the latter,<sup>20</sup> presenting a particular challenge for the identification of therapeutic targets in lung adenocarcinomas with activated *KRAS*.<sup>21</sup>


It was recently proposed that future clinical trials could target early founder events in tumour evolution,<sup>22</sup> which would presumably affect a greater majority of cells within the tumour and decrease chances of relapse. Such early molecular aberrations could represent tumour-driving alterations that would be difficult to identify within the complex heterogeneity of late stage tumours. This approach would therefore require molecular analysis of premalignant lesions, an approach that is not feasible in humans for obvious reasons. In this overview, we discuss the utility of analysing early neoplastic lesions in mouse models in order to discover new oncogenic drivers in *Kras*-driven lung adenocarcinoma.

### Early lung lesions analysis

The molecular events occurring immediately after activation of most endogenous oncogenic drivers *in vivo* are mostly unknown. We reasoned that the study of the early steps of lung tumour progression in our Cre-inducible *Kras*<sup>G12V</sup> mouse model<sup>23</sup> could uncover novel oncogenic drivers which might be obscured by complex heterogeneity in full-blown tumours and which might represent novel therapeutic targets. Following expression of the *Kras*<sup>G12V</sup> oncogene in alveolar type 2 (AT2) cells in mice, we isolated early lung hyperplastic lesions not larger than 500 cells by laser capture microdissection and analysed gene expression by standard Affymetrix array technology.<sup>24</sup> Interestingly, although all of these early hyperplastic lesions had identical gross histology, we identified two distinct molecular subgroups. One subgroup displayed substantial homology with a previously described gene expression signature present in human and mouse advanced lung adenocarcinomas<sup>19</sup> (figure 1A). We designated the tumours identified by this molecular signature as H2. The second subgroup (H1), displayed a signature similar to that obtained from the neighbouring normal alveolar parenchyma. We next compared the expression signatures of H1 and H2 to those of full-blown adenocarcinomas 10 months after activation of *Kras* by Ad-Cre infection. Our advanced adenocarcinomas exhibited an expression profile similar to that previously reported in adenocarcinomas with *KRAS* activation across species.<sup>19</sup> We additionally found our advanced adenocarcinomas could be clustered into two different subgroups that we designated as T1 and T2. According to Gene Set Enrichment Analysis (GSEA), one expression signature correlated with the profile of H1 and was designated as T1. It is reasonable to argue that this signature is associated with lesions that did not undergo major transcriptional changes during tumour progression. While the second signature, designated as T2, still maintained a significant correlation with the profiling observed in advanced human and murine lung adenocarcinomas<sup>19</sup> the top 50 up-regulated genes that defined H2 were not shared by the T2 signature, suggesting that the major molecular aberrations defining the H2 signature were obscured by the increasing molecular complexity in T2 adenocarcinomas (figure 1B). Taken together, these findings suggest that the aggressive nature of advanced tumours is determined early regardless of the mutations and transcriptional changes that may occur during tumour progression. These findings additionally highlight the advantage of analysing early hyperplastic lesions to identify tumour-driving events that might be masked by the molecular heterogeneity that is present in more advanced *KRAS*-driven lung.

### Target validation

If early *Kras* oncogenic mediators are important for both tumour onset and tumour progression, then the majority of cells in full-blown lung tumours should depend on these mediators for growth and survival. One



**Figure 1** Early lesion analysis to identify potential targets for therapeutic intervention. (A).  $Kras^{G12V}$ -driven early lung lesions ( $\leq 500$  cells) were microdissected and analysed by standard Affymetrix technology. Tumour signatures clustered in two distinct groups, one of which resembled normal lung alveolar cells (H1) and the other one aggressive murine and human lung adenocarcinoma (H2). The top-scoring gene of the H2 signature was the Discoidin Domain Receptor 1 (*DDR1*). (B).  $Kras^{G12V}$ -driven lung tumours (10 months after Ad-Cre infection) were isolated and analysed by standard Affymetrix technology. Tumour signatures clustered in two distinct groups, T1 and T2. H2 signature was diluted in the T2 signature. (C).  $Kras^{G12V}; Ddr1^{-/-}$  mice survived longer and have reduced tumour size/number compared to control  $Kras^{G12V}; Ddr1^{+/+}$  mice.

such candidate mediator identified by our analysis was the Discoidin Domain Receptor 1 (*Ddr1*) gene, which was the top-scoring upregulated gene in our ‘early aggressive’ hyperplastic H2 signature, and was also a particularly interesting therapeutic target because it encodes for a receptor tyrosine kinase (thus, potentially druggable). *DDR1* becomes activated on collagen binding which allows it to control the remodelling of the extracellular matrix and cell migration. Following binding to collagen, *Ddr1* triggers the activation of several downstream signalling pathways such as MAPK, PI3K and Notch pathways<sup>25</sup>—which have been linked to the development of a variety of cancers, including lung, breast, brain, prostate, liver and pancreas as well as lymphoma and leukaemia.<sup>25–27</sup> Intriguingly, *DDR1* has already been identified by a quantitative phosphoproteomic screening as the most abundant phosphorylated protein in human NSCLC<sup>28</sup> and has been shown to correlate with poor prognosis in human lung adenocarcinoma.<sup>29</sup> However, the role of *DDR1* in lung cancer progression and its potential as a therapeutic target is currently unknown. In order to investigate the role of *Ddr1* in  $Kras^{G12V}$ -driven lung adenocarcinoma we crossed our inducible  $Kras^{G12V}$  knocked-in model with

*Ddr1*<sup>-/-</sup> mice.<sup>30</sup>  $Kras^{G12V}; Ddr1^{-/-}$  mice exhibited longer survival, displayed decreased tumour number and size and had a higher adenoma to adenocarcinoma ratio than  $Kras^{G12V}; Ddr1^{+/+}$  control mice, suggesting that the absence of *Ddr1* impairs adenocarcinoma progression (figure 1C).

To explore the possibility that pharmacological *Ddr1* inhibition in vivo is a feasible strategy to treat lung adenocarcinomas in humans, we carried out preclinical studies in mice. To do this, we treated mice bearing  $Kras^{G12V}$ -driven lung tumours over a period of two months with the recently developed oral *Ddr1* inhibitor 7rh<sup>31</sup> and measured tumour progression by CT scanning. Interestingly, tumours demonstrating the most significant responses at the end of the treatment were those expressing high levels of the *Ddr1* receptor by immunohistochemistry staining.<sup>24</sup> In order to look for synthetic lethal drug combinations that could boost the therapeutic efficacy of the *Ddr1* inhibitor alone we considered the pathways known to be regulated by *Ddr1* in cancer cells. We chose the Notch pathway given that it is required for *Ddr1*-mediated prosurvival signalling<sup>32</sup> and is also necessary for *Kras*-driven lung adenocarcinoma progression.<sup>33</sup> Combined treatment with *Ddr1* and

Notch inhibitors was more potent than Ddr1 inhibitor alone in inducing apoptosis and impaired tumour growth even in the more aggressive *Kras*<sup>G12V</sup>; *Trp53*-null lung adenocarcinomas. Hence, both genetic and pharmacological inhibition of Ddr1 in *Kras*-driven lung adenocarcinoma impedes tumour progression.

### Orthotopic lung PDX

Patients carrying *KRAS*-mutant lung adenocarcinoma are currently treated with platinum-doublet chemotherapy (eg, carboplatin and paclitaxel plus bevacizumab or cisplatin plus pemetrexed) as first-line treatment. In order to compare the efficacy of our therapy with the current standard of care treatment, mice bearing *Kras*<sup>G12V</sup>; *Trp53*-null lung tumours were treated in parallel with either Ddr1/Notch targeted therapy or standard chemotherapy. CT scan imaging revealed that the combined targeted therapy is at least comparable to standard chemotherapy in terms of tumour volume reduction, but histopathological analysis showed that Ddr1/Notch therapy is more potent in inducing tumour necrosis.<sup>24</sup>

Finally, we extrapolated our findings in mice to human disease by developing an orthotopic model of patient-derived lung xenografts (ortho-PDX). Of note, this therapeutic validation was accomplished with a combination of drugs that are currently either Food and Drug Administration (FDA) approved (dasatinib to target DDR1) or in advanced clinical evaluation (demcizumab, an anti-DLL4 antibody to interfere with Notch signalling), which would permit for rapid testing in the clinical trials.


In three ortho-PDXs, each derived from different patients carrying concomitant *KRAS* mutations and *TP53* deletions, we observed that combined inhibition of DDR1/Notch1 signalling dampened important signalling pathways required for tumour progression and survival to a greater extent than that achieved by standard chemotherapy. This was accompanied by increased apoptosis and necrosis resulting in a substantial reduction in tumour volume. Furthermore, follow-up assessment by positron emission tomography (PET) demonstrated a long-lasting response to dasatinib/demcizumab compared to standard chemotherapy (figure 2A). Importantly, the treatment with dasatinib/demcizumab significantly delayed the re-emergence of tumour growth when compared with standard chemotherapy following discontinuation of both regimens. This observation supports the notion that targeting oncogenic events present in early aggressive lesions, such as DDR1 upregulation, can be an efficacious therapeutic strategy in advanced tumours that prevents disease relapse.

### DISCUSSION

By analysing early hyperplastic lesions in AT2 cells with activation of a resident *Kras*<sup>G12V</sup> oncogene, we uncovered two distinct transcriptional signatures that arise early during tumorigenesis that we have designated as

H1 and H2. Whereas the H1 signature closely resembles that of normal lung cells, that of H2 is highly related to a signature previously identified in advanced lung adenocarcinomas of both mouse and human origin.<sup>19</sup> These distinct transcriptional profiles are not due to histological differences within the early hyperplastic areas, supported by the fact that all cells within the foci unambiguously expressed the AT2-specific marker surfactant protein C (SPC).<sup>34</sup> It has been recently reported that a minor subpopulation of adult progenitor AT2 cells function as lung stem cells, which self-renew on oncogenic *Kras* expression.<sup>35</sup> Our aggressive H2 signature displayed significant overlap with that of this progenitor AT2 cell population, whereas H1 did not. Interestingly, we found early hyperplastic lesions with the progenitor-like H2 signature at a similar frequency to those with an H1 signature. Given the rare frequency of the progenitor population in normal lung, this could be explained by a greater susceptibility of progenitors to Ras-mediated transformation. However, we cannot exclude the possibility that AT2 cells, conventionally described as a single SPC-positive cell population, might comprise different, yet unidentified subpopulations of cells with variable responses on oncogenic *Kras* activation. Indeed, preliminary data from our laboratory using a Ddr1 probe suggest that not all AT2 cells express Ddr1 mRNA, thus raising the possibility that SPC+ AT2 cells do not represent a homogeneous population.

Cancer heterogeneity arises from the selective outgrowth of distinct subclones within a tumour that have acquired distinct molecular profiles that confer a proliferative and survival advantage.<sup>22–26</sup> In our study we utilised an unbiased gene expression profiling approach to formally demonstrate that inter-tumour heterogeneity, at least in *Kras*<sup>G12V</sup>-driven lung adenocarcinoma, appears early during tumour evolution. Of the two signatures identified, the H1 profile remained stable over time and was detectable even in late stage adenocarcinomas months after oncogene expression. The stability of this H1 signature, which probably represents a less aggressive form of the disease, suggests that the progression towards an aggressive phenotype is not merely a time-dependent process that invariably occurs following oncogene activation. In contrast, the H2 signature became masked as early hyperplastic lesions progressed to yield advanced adenocarcinomas so much so that *Ddr1*, the top marker in early H2 hyperplastic lesions, was no longer recognised as a highly up-regulated gene in advanced T2 tumours. This is probably due to the high degree of variability of Ddr1 levels in late stage tumours and underscores the necessity to perform molecular profiling in early hyperplastic lesions due to the limitations posed by tumour heterogeneity in full-blown tumours. In addition to being the most highly up-regulated gene in early aggressive lesions, the fact that Ddr1 is the most hyper-phosphorylated protein in advanced human lung tumours<sup>28</sup> suggested that it could be a valid therapeutic target. To test this hypothesis, we genetically and



**Figure 2** Therapeutic validation in orthotopic lung PDX. (A). Biopsies from patients carrying KRAS-mutant;TP53-deficient lung adenocarcinomas were orthotopically implanted in *CrI:NU-Foxn1<sup>nu</sup>* mice and subjected to treatment with either vehicle, cisplatin/paclitaxel chemotherapy or dasatinib/demcizumab. Positron emission tomography (PET) follow-up demonstrated a better response when compared with chemotherapy. CD31 immunostaining showed a substantial decrease of the endothelial compartment in tumours subjected to the combined therapy. (B). Percentages of alteration frequencies identified in different NSCLC studies obtained from the TCGA database (<http://www.cbioportal.org>). Red=gene amplification; green=mutation. PDX, patient-derived xenograft; NSCLC, non-small cell lung carcinoma.

pharmacologically inhibited *Ddr1* in murine models of lung cancer. *Ddr1* deficiency significantly impaired tumour development and progression of *Kras*<sup>G12V</sup>-driven lung adenocarcinomas in a *Trp53*-proficient background, leading to prolonged overall survival. Pharmacological inhibition of *Ddr1* with the selective *Ddr1* inhibitor 7rh also yielded a favourable therapeutic response. Importantly, *Ddr1* seems to exert a dose-dependent effect on tumour growth as suggested by the fact that even *Ddr1*<sup>+/-</sup> mice showed intermediate improved survival between that of *Ddr1*<sup>+/+</sup> and *Ddr1*<sup>-/-</sup> mice, indicating that even partial pharmacological inhibition of *Ddr1* is likely to reduce tumour growth. Other selective *Ddr1* inhibitors including receptor-blocking antibodies have been recently described, reflecting an increasing interest in targeting this tyrosine kinase receptor for cancer treatment.<sup>31 37-39</sup>

Though genetic and pharmacological inhibition of *Ddr1* alone in *Kras*<sup>G12V</sup>/*Trp53*-null tumours extended survival and slowed tumour growth, the therapeutic effects were not complete. Thus, in order to increase the therapeutic efficacy of *Ddr1* inhibition, we treated mice with a combination of 7rh and a  $\gamma$ -secretase inhibitor, which interferes with Notch activation. This strategy was based on the fact that Notch activity is required for lung

adenocarcinoma progression.<sup>32 33 40 41</sup> Additionally, Notch has been reported to mediate cellular survival downstream of *Ddr1* in a ligand-independent fashion,<sup>32</sup> which would permit for residual Notch signalling in the setting of 7rh-mediated *Ddr1* inhibition, which targets the extracellular domain. Notably, the combination of 7rh and  $\gamma$ -secretase inhibitors displayed a significant inhibitory effect on the growth of aggressive *Kras*<sup>G12V</sup>-driven/*Trp53*-null lung adenocarcinomas, whereas neither inhibitor used alone exerted appreciable therapeutic activity. This additive therapeutic effect suggests that, in addition to the known role of Notch signalling downstream of *DDR1*, Notch and *DDR1* also have non-redundant roles in driving lung adenocarcinoma. Of further note, tumours treated with 7rh alone displayed a robust reduction of *Hes1*, a canonical downstream target of the Notch pathway, an effect which was not seen in the surrounding normal tissue.<sup>24</sup> The reason for tumour-specific (7rh-mediated) inhibition of Notch1 is uncertain but deserves further investigation and has obvious advantageous implications in terms of minimising toxic side effects in healthy tissue.

This work suggests that *DDR1* and *HES1* levels can be used as biomarkers in human lung adenocarcinoma to stratify patients who more likely can benefit from

combined Notch and DDR1 inhibitor treatment. We probed lung adenocarcinoma Tissue Microarrays and we found that ~75% of *KRAS*-mutant lung adenocarcinoma expressed high levels of DDR1, whereas ~60% co-expressed high levels of both DDR1 and HES1. Unfortunately, pan-Notch inhibitors have limited clinical utility due to gastrointestinal toxicity as a consequence of Notch1/2 inhibition in intestinal crypts.<sup>42–43</sup> While Notch1 has been shown to play an important role in lung adenocarcinoma progression, Notch3 has also been reported to regulate lung cancer stem cell self-renewal and propagation.<sup>40–44</sup> Identification and more selective therapeutic targeting of the individual Notch family member that most significantly mediates Ddr1's effects will lead to combined drug regimens for adenocarcinoma patients with tolerable side effects.

To extrapolate the applicability of our findings to human tumours, we assessed the efficacy of DDR1/Notch inhibition in a human lung orthotopic PDX (orthoxenograft) model, using human lung adenocarcinomas mutant for *KRAS* treated with demcizumab to block Notch signalling or dasatinib for DDR1 inhibition. Dasatinib is an already-FDA approved small molecule tyrosine kinase inhibitor that was initially isolated as a dual SRC/ABL inhibitor and was later found to have broader inhibitory activity against other targets such as DDR1, cKIT and PDGFR.<sup>45</sup> Though lack of specificity is generally undesirable for kinase inhibitors, this feature of dasatinib most likely has beneficial effects in the context of DDR1 inhibition, since DDR1 and SRC are engaged in a regulatory loop<sup>46</sup> whereby dasatinib-mediated inhibition of SRC leads to vertical inhibition of the pathway. Demcizumab is a monoclonal antibody that selectively targets Delta-like ligand 4 (DLL4), an activator of the Notch signalling pathway and a mediator that promotes tumour angiogenesis. This antibody is currently in phase II clinical trials and is intended to have both anticancer stem cell and antiangiogenic activity. The dasatinib/demcizumab combination treatment of PDXs resulted in potent inhibition of key signalling pathways that drive tumour progression and survival, reducing the intratumoral fluorodeoxyglucose-PET signal and inducing tumour shrinkage more effectively than chemotherapy. We further observed a substantial decrease of the endothelial compartment in tumours subjected to the combined therapy as measured by CD31 immunostaining, presumably due to the antiangiogenic effects of demcizumab (figure 2A). Given these studies employing primary human tumour samples, further investigation is warranted into dual DDR1/Notch inhibition as a therapeutic strategy for *KRAS*-driven lung adenocarcinoma expressing DDR1, regardless of the *TP53* status.

Finally, several *DDR1* mutations have been identified in various independent studies involving human NSCLC (figure 2B), with ~50% of these alterations being located within the kinase domain. Given their clustering within this region, it is tempting to speculate that these

mutations may be functionally relevant (and selected for) during disease progression. It would be of interest to investigate the presence of such mutations specifically in tumours from patients after relapse following chemotherapy. The presence of DDR1 mutations in these cases would support using DDR1 inhibitors to treat chemoresistant individuals or patients with residual disease following chemotherapy, who currently lack therapeutic options.

## Highlights

- ▶ The study of early lesions as a new approach to look for valuable therapeutic targets could, in principle, be extended to other types of solid tumour in relevant mouse models.
- ▶ The aggressive nature of Kirsten rat sarcoma viral oncogene homologue (*Kras*<sup>G12V</sup>)-driven lung adenocarcinoma is determined early during tumour development.
- ▶ The receptor tyrosine kinase Ddr1 is required for *Kras*<sup>G12V</sup>-driven lung adenocarcinoma progression in vivo.
- ▶ Dual pharmacological inhibition of Discoidin Domain Receptor 1 DDR1 and Notch pathways hampers the growth of murine and human *KRAS*-mutant; *TP53*-deficient lung adenocarcinoma.
- ▶ Preclinical tests in lung orthotopic patient-derived xenografts performed with Food and Drug Administration-approved drug dasatinib, together with demcizumab (which is currently in phase II as a first-line therapy in combination with carboplatin/pemetrexed chemotherapy for non-small cell lung carcinoma) show promising outcomes.

## Author affiliations

<sup>1</sup>Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

<sup>2</sup>Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

<sup>3</sup>Department of Medical Oncology, Multidisciplinary Thoracic Oncology Unit, Catalan Institute of Oncology, Barcelona, Spain

<sup>4</sup>Xenopat S.L., Business Biocubator, Bellvitge Health Science Campus, Barcelona, Spain

<sup>5</sup>Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain

<sup>6</sup>Bioinformatics Unit, Structural Biology and Biocomputing Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

<sup>7</sup>Tumour Suppression, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

**Contributors** CA and DS wrote the manuscript with contributions from all other authors.

**Funding** This work was supported by AECC (Asociación Española Contra el Cáncer) fellowship to CA. MB is the recipient of an Endowed Chair from the AXA Research Fund and was supported by grants from the European Research Council (ERC-AG/250297-RAS AHEAD), EU-Framework Programme (HEALTH-F2-2010-259770/LUNGTARGET and HEALTH-2010-260791/EUROCANPLATFORM), Spanish Ministry of Economy and Competitiveness (SAF2011-30173 and SAF2014-59864-R) and Autonomous Community of

Madrid (S2011/BDM-2470/ONCOCYCLE). Ernest Nadal was supported by a Juan Rodés fellowship from the Carlos III Health Institute (JR13/0002).

**Competing interests** None declared.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

1. Ettinger DS, Akerley W, Borghaei H, *et al.* Non-small cell lung cancer, version 2.2013. *J Natl Compr Canc Netw* 2013;11:645–53; quiz 653.
2. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132:29S–55S.
3. Santos E, Martin-Zanca D, Reddy EP, *et al.* Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. *Science* 1984;223:661–4.
4. Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. *Drugs* 2012;72:28–36.
5. Meng D, Yuan M, Li X, *et al.* Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. *Lung Cancer* 2013;81:1–10.
6. Nadal E, Chen G, Prensner JR, *et al.* KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. *J Thorac Oncol* 2014;9:1513–22.
7. Shepherd FA, Domerg C, Hainaut P, *et al.* Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. *J Clin Oncol* 2013;31:2173–81.
8. Rulli E, Marabese M, Torri V, *et al.* Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. *Ann Oncol* 2015;26:2079–84.
9. Ostrem JM, Peters U, Sos ML, *et al.* K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature* 2013;503:548–51.
10. Westover KD, Janne PA, Gray NS. Progress on Covalent Inhibition of KRASG12C. *Cancer Discov* 2016;6:233–4.
11. Kwon MC, Berns A. Mouse models for lung cancer. *Mol Oncol* 2013;7:165–77.
12. Chen Z, Fillmore CM, Hammerman PS, *et al.* Non-small-cell lung cancers: a heterogeneous set of diseases. *Nat Rev Cancer* 2014;14:535–46.
13. Chen Z, Cheng K, Walton Z, *et al.* A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature* 2012;483:613–17.
14. Jänne PA, Shaw AT, Pereira JR, *et al.* Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncol* 2013;14:38–47.
15. Goldman JW, Shi P, Reck M, *et al.* Treatment Rationale and Study Design for the JUNIPER Study: a Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutati. *Clin Lung Cancer* 2016;17:80–4.
16. Puyol M, Martín A, Dubus P, *et al.* A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. *Cancer Cell* 2010;18:63–73.
17. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? *Nat Rev Cancer* 2012;12:323–34.
18. Alexandrov LB, Nik-Zainal S, Wedge DC, *et al.* Signatures of mutational processes in human cancer. *Nature* 2013;500:415–21.
19. Sweet-Cordero A, Mukherjee S, Subramanian A, *et al.* An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet* 2005;37:48–55.
20. Starmans MHW, Pintilie M, Chan-Seng-Yue M, *et al.* Integrating RAS status into prognostic signatures for adenocarcinomas of the lung. *Clin Cancer Res* 2015;21:1477–86.
21. Skoulidis F, Byers LA, Diao L, *et al.* Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discov* 2015;5:861–78.
22. Burrell RA, Swanton C. The evolution of the unstable cancer genome. *Curr Opin Genet Dev* 2014;24:61–7.
23. Guerra C, Mijimolle N, Dhawahir A, *et al.* Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. *Cancer Cell* 2003;4:111–20.
24. Ambrogio C, López-Gómez G, Falcone M, *et al.* Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. *Nat Med* 2016;22:270–7.
25. Valiathan RR, Marco M, Leitinger B, *et al.* Discoidin domain receptor tyrosine kinases: new players in cancer progression. *Cancer Metastasis Rev* 2012;31:295–321.
26. Borza CM, Pozzi A. Discoidin domain receptors in disease. *Matrix Biol* 2014;34:185–92.
27. Valencia K, Ormazabal C, Zanduetta C, *et al.* Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. *Clin Cancer Res* 2012;18:969–80.
28. Rikova K, Guo A, Zeng Q, *et al.* Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 2007;131:1190–203.
29. Miao L, Zhu S, Wang Y, *et al.* (2013) Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. *Med Oncol* 2013;30:626.
30. Vogel WF, Aszódi A, Alves F, *et al.* Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. *Mol Cell Biol* 2001;21:2906–17.
31. Gao M, Duan L, Luo J, *et al.* Discovery and optimization of 3-(2-(Pyrzolo[1,5-a]pyrimidin-6-yl)ethyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. *J Med Chem* 2013;56:3281–95.
32. Kim HG, Hwang SY, Aaranson SA, *et al.* DDR1 receptor tyrosine kinase promotes pro-survival pathway through Notch1 activation. *J Biol Chem* 2011;286:17672–81.
33. Maraver A, Fernandez-Marcos PJ, Herranz D, *et al.* Therapeutic effect of  $\gamma$ -secretase inhibition in Kras G12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. *Cancer Cell* 2012;22:222–34.
34. Mainardi S, Mijimolle N, Francoz S, *et al.* Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. *Proc Natl Acad Sci USA* 2014;111:255–60.
35. Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. *Nature* 2014;507:190–4.
36. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. *Nature* 2013;501:328–37.
37. Canning P, Tan L, Chu K, *et al.* Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. *J Mol Biol* 2014;426:2457–70.
38. Carafoli F, Mayer MC, Shiraiishi K, *et al.* Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling. *Structure* 2012;20:688–97.
39. Kim H-G, Tan L, Weisberg EL, *et al.* Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. *ACS Chem Biol* 2013;8:2145–50.
40. Licciulli S, Avila JL, Hanlon L, *et al.* (2013) Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. *Cancer Res* 2013;73:5974–84.
41. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. *Nat Rev Cancer* 2011;11:338–51.
42. Van Es JH, van Gijn ME, Riccio O, *et al.* Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. *Nature* 2005;435:959–63.
43. Staal FJT, Langerak AW. Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. *Haematologica* 2008;93:493–7.
44. Zheng Y, de la Cruz CC, Sayles LC, *et al.* A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. *Cancer Cell* 2013;24:59–74.
45. Karaman MW, Herrgard S, Treiber DK, *et al.* A quantitative analysis of kinase inhibitor selectivity. *Nat Biotechnol* 2008;26:127–32.
46. Leitinger B. Discoidin domain receptor functions in physiological and pathological conditions. *Int Rev Cell Mol Biol* 2014;310:39–87.